Ovid Therapeutics (OVID) reported quarterly earnings of $0.06 per share for the quarter ended December 2025, exceeding the Zacks Consensus Estimate of a loss of $0.10 per share and improving from a loss of $0.13 per share a year earlier. This marks an earnings surprise of +158.71%.
Additionally, the company generated revenues of $0.72 million, surpassing the consensus estimate by 195.47% compared to revenues of $0.08 million in the same quarter last year. Ovid Therapeutics has outperformed revenue estimates three times in the past four quarters.
So far in 2023, Ovid Therapeutics shares have risen approximately 23.3%, contrasting with a 1.9% decline in the S&P 500. Looking ahead, analysts predict a consensus EPS estimate of -$0.08 on revenues of $0.2 million for the upcoming quarter.
